TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: angiogenic and tumor growth factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mucociliary Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Global Impression-Improvement (CGI-I) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral Breast Tumor Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: T1/2 of Radiocarbon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Plasma Clearance (CL/F) of Olesoxime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant reported spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival rate at 5.5 years
Endpoint domain: Mortality/survival
Primary endpoint: EHP-5 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Full Scale IQ Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to autonomous neuropathic ulcers and Amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to peripheral Macro-Vascular Disease, chronic Foot ulcers and Amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time of emergence from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p70s6 kinase inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Glycemic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline verbal declarative memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline executive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TNF-α Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhaled corticosteroid adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Site Feasibility Metrics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Confidence in Therapy - Oncology Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Supervision Evaluation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Overall Response Rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of light therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of heparin withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left atrial appendage closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of skin flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Losing at Least 5% Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization score of endotracheal landmark structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: difficulty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lateral prefrontal cortex activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in modified Vancouver scar scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patellar height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Freedom of arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD severity score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of life traumatic events
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Unique proteins or peptides associated with prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV Self-test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum metabolite profile of niacinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in subjective appetite response to pecan or pretzel snack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum glucose following snack consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum insulin following snack consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Direct Medical Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Histopathologic Regression of Target Atypical Nevi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Heart failure readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salivary cotinine or urinary anabasine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement and accuracy of gastric pH measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of samples collected for NG tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of sample accuracy for NG tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet reactivity inhibition measured by the VASP index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Performance of the sequence learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Combined hard cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain during nasal pack removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative evolution of the wound surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in metabolic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of fully immunized children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in E/I Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Valsalva Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Resting Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ritalinic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported use of LARC method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increase in airway neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of clinical and radiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Got Access to Dacomitinib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: TDC Tumor Differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TDC Inter-Breast Differentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TDC reference values for breasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: acute patient safety
Endpoint domain: Adverse events/effects
Primary endpoint: number of anesthetized patients who died in the perioperative period
Endpoint domain: Mortality/survival
Primary endpoint: Immune Response to GM-CSF With a Pneumococcal Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects experiencing serious adverse events (SAEs) and/or adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical interventions required during LSG
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnosis of Obstructive Sleep Apnea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Serum Risk Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimum PEEP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time spent engaged in screen-time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of consumption of energy-dense snack foods, fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myometrium thickness after isthmocele correction procedure (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of new cysts in the area of caesarean sectio after isthmocele correction procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction after isthmocele correction procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Literary skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Percentage Change in Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Percent Change in Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of endotracheal tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of anesthesia maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of persistent or recurrent intestinal metaplasia/dysplasia and esophageal and gastric lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in ratio of estrogen metabolites 2OHE1:16αOHE1 in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inter-observer agreement of the Spigelman Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control measured by HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic parameters of R1450 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Health of Skin EASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Health of Skin IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Health of Skin BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Hepatic Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of WCK 2349 and WCK 771
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Visual acuity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Satisfaction with information from health care professionals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Variation in continuous cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective nociceptive threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With no Evidence of Further Scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24hr voiding diary reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetics of avanafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change of Fasting Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in motivation levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon Cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerated dose (MTD) defined by dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Safety/Tolerability of Single Ascending Doses
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration of Single Ascending Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration of Single Ascending Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption rate of solabegron and oxybutynin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel Cleanliness during colonoscopy (Boston Bowel Preparation Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bowel Cleanliness during colonoscopy (Ottawa Bowel Preparation Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful Resolution of LI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preprandial ketonemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic profile below pregnancy target capillary blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Acute Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 12-Month Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acute Safety Success
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 12-Month Safety Success
Endpoint domain: Adverse events/effects
Primary endpoint: anti-tumour activity using FDG-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anti-tumour activity using RECISTv1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experienced Cytopenias
Endpoint domain: Adverse events/effects
Primary endpoint: Specific airway conductance (sGAW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Symptoms-PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Symptoms-SANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of men with negative or equivocal imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a Myocardial Perfusion Defect Indicating Significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of a Myocardial Perfusion Defect Excluding Significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-efficacy for HIV Prevention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of Condom Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early response assessment of induction chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Brain Barrier Penetration of RAPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Improvement in Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of bone persorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Physician's Wart Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Device Feasibility based on image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of microscopic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration of Lidocaine (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants enrolled in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of enrolled participants at end of study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average number of completed exercise session per-week for the study duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue characteristics of thoracolumbar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration of Levothyroxine (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under Serum Concentration-Time Curve of Levothyroxine (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants meeting VH CCSVI CDUS criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of propofol in liver diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of propofol in liver diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Active Range of Motion (AROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily absorbed zinc (TAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mood States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute variation of HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes